UNLABELLED: Background Primary mediastinal large B-cell lymphoma is a rare lymphoma accounting for no more than 3% of all B-cell lymphomas in children and adolescents. However, patients in this young age group with this lymphoma have the shortest event-free survival of patients with any B-cell lymphoma under current standard chemotherapy protocols. Lymphomas with features intermediate between primary mediastinal large B-cell lymphoma and classical Hodgkin's lymphoma (mediastinal gray zone lymphomas) have been acknowledged in the latest World Health Organization classification. Recent studies suggest that mediastinal gray zone lymphomas have an aggressive clinical course whereas patients, at least adult ones, with primary mediastinal large B-cell lymphoma might respond very well to chemotherapy in combination with anti-CD20 antibody. DESIGN AND METHODS: We aimed to evaluate whether biological differences or so far unrecognized admixed mediastinal gray zone lymphomas might explain the relatively poor outcome of pediatric patients with apparent primary mediastinal large B-cell lymphoma. We, therefore, performed a retrospective histopathological, immunohistochemical and interphase cytogenetic analysis of 52 pediatric lymphomas. RESULTS: The childhood primary mediastinal large B-cell lymphomas (n=44) showed a similar pattern of histology, immunophenotype and gains at 9p (59%) and 2p (41%) as adult cases, as determined from published data. We identified only four so far unrecognized cases of mediastinal gray zone lymphoma among 52 lymphomas registered in previous trials. Conclusions Mediastinal gray zone lymphoma is very rare in children and adolescents. It does, therefore, seem unlikely that these lymphomas account for the unsatisfactory clinical results with current therapy protocols in pediatric patients. These data have major implications for the design of future treatment protocols for mediastinal lymphomas in children and adolescents.
UNLABELLED: Background Primary mediastinal large B-cell lymphoma is a rare lymphoma accounting for no more than 3% of all B-cell lymphomas in children and adolescents. However, patients in this young age group with this lymphoma have the shortest event-free survival of patients with any B-cell lymphoma under current standard chemotherapy protocols. Lymphomas with features intermediate between primary mediastinal large B-cell lymphoma and classical Hodgkin's lymphoma (mediastinal gray zone lymphomas) have been acknowledged in the latest World Health Organization classification. Recent studies suggest that mediastinal gray zone lymphomas have an aggressive clinical course whereas patients, at least adult ones, with primary mediastinal large B-cell lymphoma might respond very well to chemotherapy in combination with anti-CD20 antibody. DESIGN AND METHODS: We aimed to evaluate whether biological differences or so far unrecognized admixed mediastinal gray zone lymphomas might explain the relatively poor outcome of pediatric patients with apparent primary mediastinal large B-cell lymphoma. We, therefore, performed a retrospective histopathological, immunohistochemical and interphase cytogenetic analysis of 52 pediatric lymphomas. RESULTS: The childhood primary mediastinal large B-cell lymphomas (n=44) showed a similar pattern of histology, immunophenotype and gains at 9p (59%) and 2p (41%) as adult cases, as determined from published data. We identified only four so far unrecognized cases of mediastinal gray zone lymphoma among 52 lymphomas registered in previous trials. Conclusions Mediastinal gray zone lymphoma is very rare in children and adolescents. It does, therefore, seem unlikely that these lymphomas account for the unsatisfactory clinical results with current therapy protocols in pediatric patients. These data have major implications for the design of future treatment protocols for mediastinal lymphomas in children and adolescents.
Authors: José I Martín-Subero; Stefan Gesk; Lana Harder; Takashi Sonoki; Philip W Tucker; Brigitte Schlegelberger; Werner Grote; Francisco J Novo; María J Calasanz; Martin L Hansmann; Martin J S Dyer; Reiner Siebert Journal: Blood Date: 2002-02-15 Impact factor: 22.113
Authors: Roland A Ventura; Jose I Martin-Subero; Margaret Jones; Joanna McParland; Stefan Gesk; David Y Mason; Reiner Siebert Journal: J Mol Diagn Date: 2006-05 Impact factor: 5.568
Authors: J F García; M Mollejo; M Fraga; J Forteza; J A Muniesa; M Pérez-Guillermo; C Pérez-Seoane; T Rivera; P Ortega; M A Piris Journal: Histopathology Date: 2005-07 Impact factor: 5.087
Authors: K Seidemann; M Tiemann; I Lauterbach; G Mann; I Simonitsch; K Stankewitz; M Schrappe; M Zimmermann; C Niemeyer; R Parwaresch; H Riehm; A Reiter Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544
Authors: Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp Journal: Blood Date: 2003-08-21 Impact factor: 22.113
Authors: T Rüdiger; E S Jaffe; G Delsol; C deWolf-Peeters; R D Gascoyne; A Georgii; N L Harris; M E Kadin; K A MacLennan; S Poppema; H Stein; L E Weiss; H K Müller-Hermelink Journal: Ann Oncol Date: 1998 Impact factor: 32.976
Authors: M A Weniger; K Pulford; S Gesk; S Ehrlich; A H Banham; L Lyne; J I Martin-Subero; R Siebert; M J S Dyer; P Möller; T F E Barth Journal: Leukemia Date: 2006-07-27 Impact factor: 11.528
Authors: Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt Journal: J Exp Med Date: 2003-09-15 Impact factor: 14.307
Authors: Mary Gerrard; Ian M Waxman; Richard Sposto; Anne Auperin; Sherrie L Perkins; Stanton Goldman; Lauren Harrison; Ross Pinkerton; Keith McCarthy; Martine Raphael; Catherine Patte; Mitchell S Cairo Journal: Blood Date: 2012-11-13 Impact factor: 22.113
Authors: Ji Yuan; George Wright; Andreas Rosenwald; Christian Steidl; Randy D Gascoyne; Joseph M Connors; Anja Mottok; Dennis D Weisenburger; Timothy C Greiner; Kai Fu; Lynette Smith; Lisa M Rimsza; Elaine S Jaffe; Elias Campo; Antonio Martinez; Jan Delabie; Rita M Braziel; James R Cook; German Ott; Julie M Vose; Louis M Staudt; Wing C Chan Journal: Am J Surg Pathol Date: 2015-10 Impact factor: 6.394
Authors: Franziska C Eberle; Jaime Rodriguez-Canales; Lai Wei; Jeffrey C Hanson; J Keith Killian; Hong-Wei Sun; Lisa G Adams; Stephen M Hewitt; Wyndham H Wilson; Stefania Pittaluga; Paul S Meltzer; Louis M Staudt; Michael R Emmert-Buck; Elaine S Jaffe Journal: Haematologica Date: 2011-04 Impact factor: 9.941
Authors: Véronique Minard-Colin; Laurence Brugières; Alfred Reiter; Mitchell S Cairo; Thomas G Gross; Wilhelm Woessmann; Birgit Burkhardt; John T Sandlund; Denise Williams; Marta Pillon; Keizo Horibe; Anne Auperin; Marie-Cécile Le Deley; Martin Zimmerman; Sherrie L Perkins; Martine Raphael; Laurence Lamant; Wolfram Klapper; Lara Mussolin; Hélène A Poirel; Elizabeth Macintyre; Christine Damm-Welk; Angelo Rosolen; Catherine Patte Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544